| Not Yet Recruiting | A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myel NCT07053020 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Ac NCT07423104 | University of Rochester | Phase 2 |
| Not Yet Recruiting | TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT NCT07302776 | Stanford University | Phase 1 |
| Recruiting | MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib NCT07463651 | The First Affiliated Hospital of Soochow University | Phase 3 |
| Not Yet Recruiting | VAH vs VA in Newly Diagnosed Elderly AML NCT07469046 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 3 |
| Not Yet Recruiting | Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood- NCT07060001 | The Methodist Hospital Research Institute | Phase 2 |
| Not Yet Recruiting | CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia NCT07464951 | Stephan Grupp MD PhD | Phase 1 |
| Not Yet Recruiting | Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG) NCT07507825 | First People's Hospital of Hangzhou | Phase 2 |
| Recruiting | Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML NCT07500441 | Peking University People's Hospital | — |
| Not Yet Recruiting | Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia NCT07486726 | Shanghai Jiao Tong University School of Medicine | Phase 1 / Phase 2 |
| Not Yet Recruiting | Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Dia NCT07486479 | The First Affiliated Hospital of Soochow University | Phase 3 |
| Not Yet Recruiting | Efficacy and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in Venetoclax/Azacitidine Pretreated NCT07505160 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 |
| Recruiting | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors NCT07410494 | Essen Biotech | Phase 1 / Phase 2 |
| Recruiting | Ivosidenib as Post-HSCT Maintenance for AML NCT06707493 | Massachusetts General Hospital | Phase 2 |
| Active Not Recruiting | Effectiveness and Safety of ONUREG (Oral Azacitidine) in Chinese Patients With Acute Myeloid Leukemia NCT07458542 | Bristol-Myers Squibb | — |
| Recruiting | Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDS NCT07532824 | Institute of Hematology and Blood Transfusion, Czech Republic | Phase 1 / Phase 2 |
| Not Yet Recruiting | Harmonized Clinical and Biological Database for Integrated Research Into the Management of Pediatric Acute Mye NCT07150676 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia NCT07198867 | First Affiliated Hospital of Zhejiang University | Phase 1 |
| Recruiting | Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r A NCT07007312 | Kura Oncology, Inc. | Phase 3 |
| Recruiting | Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML NCT07451912 | The First Affiliated Hospital of Soochow University | Phase 1 / Phase 2 |
| Not Yet Recruiting | Ex Vivo T-Cell-Depleted Haploidentical Transplantation Bridging With Chimeric Antigen Receptor T-cell Therapy NCT07087847 | Ruijin Hospital | N/A |
| Recruiting | uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies NCT07109518 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 |
| Recruiting | SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies NCT07153068 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 / Phase 2 |
| Recruiting | Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients NCT06990321 | Yehui Tan | Phase 3 |
| Recruiting | Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia NCT07537738 | Peking University People's Hospital | — |
| Recruiting | Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Mini NCT07023588 | Yehui Tan | Phase 2 |
| Recruiting | Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Mal NCT07238712 | St. Petersburg State Pavlov Medical University | Phase 2 |
| Recruiting | Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomi NCT06811233 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cel NCT06869265 | Peking University People's Hospital | Phase 2 |
| Recruiting | Biomarkers in Patients With Anemia-Induced Thrombocytopenic Bleeding NCT06947044 | Donald Arnold | N/A |
| Recruiting | A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) NCT06950034 | Solu Therapeutics, Inc | Phase 1 |
| Not Yet Recruiting | Azacitidine Combined with Donor Lymphocyte Infusion for Acute Myeloid Leukemia Post-transplant Relapse Prevent NCT06754540 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 2 |
| Recruiting | A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML) NCT06773208 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Terminated | Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3:: NCT06679582 | Sutro Biopharma, Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Phase I Single-arm Clinical Study of Donor NK Cells Infusion Combined with Low-dose Interleukin-2 in the Tre NCT06641648 | Peking University First Hospital | Phase 1 |
| Not Yet Recruiting | Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenou NCT06702098 | Guangzhou Ruixin Biotechnological Co., LTD | EARLY_Phase 1 |
| Not Yet Recruiting | Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Ac NCT06652685 | Ruijin Hospital | Phase 2 |
| Recruiting | APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML NCT06634394 | Aptevo Therapeutics | Phase 1 |
| Recruiting | Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral NCT06398457 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | EARLY_Phase 1 |
| Recruiting | EX02 CAR-T Cells for Relapsed and Refractory Acute Myeloid Leukemia NCT06642025 | Zhimin Zhai | EARLY_Phase 1 |
| Recruiting | A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS NCT06372717 | Apollo Therapeutics Ltd | Phase 1 |
| Completed | Association of Ex Vivo Drug Response ( EVDR) and Clinical Outcome in Acute Myeloid Leukaemia (EXCYTE-2) NCT06648512 | Exscientia AI Limited | — |
| Completed | Assessing Refractoriness and Infectious Survival Events in AML NCT06709235 | Hospices Civils de Lyon | — |
| Not Yet Recruiting | A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia NCT06387420 | Akeso | Phase 1 / Phase 2 |
| Active Not Recruiting | Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML NCT06268574 | Ryvu Therapeutics SA | Phase 2 |
| Completed | Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPC NCT06181734 | iOMEDICO AG | — |
| Completed | VYxeoS Liposomal Italian Observational Study iN the Real Practice NCT06143839 | Jazz Pharmaceuticals | — |
| Completed | A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R NCT05665530 | Prelude Therapeutics | Phase 1 |
| Recruiting | High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT) NCT07205523 | Yigeng Cao,MD,PhD | — |
| Recruiting | A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AM NCT05756777 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed W NCT05907057 | Servier Affaires Médicales | Phase 3 |
| Terminated | CART-38 in Adult AML and MM Patients NCT05442580 | University of Pennsylvania | Phase 1 |
| Completed | Characteristics and Outcomes of Acute Myeloid Leukemia (AML) Patients Treated With Oral-Azacitidine Maintenanc NCT06565975 | Bristol-Myers Squibb | — |
| Recruiting | Venetoclax in Combination with 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Inducti NCT05833438 | University of Leipzig | Phase 2 |
| Unknown | Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acut NCT05697510 | Nantes University Hospital | Phase 1 |
| Active Not Recruiting | A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Ac NCT05520567 | Astellas Pharma Global Development, Inc. | Phase 1 / Phase 2 |
| Terminated | Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML) NCT05682170 | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Unknown | Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) NCT05291390 | Armaceutica, Inc. | Phase 2 |
| Recruiting | Niclosamide in Pediatric Patients With Relapsed and Refractory AML NCT05188170 | Stanford University | Phase 1 |
| Recruiting | Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphod NCT05092451 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Withdrawn | STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis NCT05519527 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML) NCT04777916 | Acute Leukemia French Association | — |
| Recruiting | Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with NCT06760260 | Hrain Biotechnology Co., Ltd. | EARLY_Phase 1 |
| Active Not Recruiting | Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous NCT05144243 | AbbVie | Phase 4 |
| Terminated | ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN NCT04639024 | Gwynn Long, M.D. | Phase 2 |
| Unknown | Injection of Lymphocytes From Haplo-identical Donor Following Chemotherapy in Patients With High-risk Acute My NCT04886206 | Nantes University Hospital | Phase 1 |
| Completed | Feasibility Pilot Exploring Variability in Biomarkers and PROs in AML NCT04908852 | Dana-Farber Cancer Institute | — |
| Terminated | Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azaci NCT04912063 | AbbVie | Phase 1 |
| Terminated | VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractor NCT04702425 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants of NCT04813263 | AbbVie | — |
| Active Not Recruiting | A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Pr NCT04872595 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Pharmacokinetics, Tolerability and Safety of NEX-18a NCT05048498 | Nanexa AB | Phase 1 |
| Completed | Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants Abo NCT04826523 | AbbVie | — |
| Unknown | A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mu NCT04716114 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 3 |
| Terminated | GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies NCT04824794 | Genmab | Phase 1 / Phase 2 |
| Completed | Safety and Preliminary Efficacy of Donor-derived Anti-leukemia Cytotoxic T Lymphocytes for the Prevention of L NCT06865352 | Fondazione IRCCS Policlinico San Matteo di Pavia | Phase 1 / Phase 2 |
| Completed | Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin NCT04547062 | Nantes University Hospital | Phase 1 |
| Active Not Recruiting | Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations NCT04603001 | Eli Lilly and Company | Phase 1 |
| Withdrawn | Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM) NCT04395092 | Kiadis Pharma | Phase 2 |
| Completed | A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adul NCT04266795 | Takeda | Phase 2 |
| Completed | A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Ass NCT04509622 | AbbVie | Phase 3 |
| Completed | Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML) NCT05488613 | Novartis Pharmaceuticals | — |
| Terminated | A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FM NCT04240002 | Astellas Pharma Global Development, Inc. | Phase 1 / Phase 2 |
| Withdrawn | Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies NCT05513612 | Shanghai Pudong Hospital | Phase 1 |
| Unknown | JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transpla NCT04429191 | Jasper Therapeutics, Inc. | Phase 1 |
| Recruiting | A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML NCT04275518 | Ascentage Pharma Group Inc. | Phase 1 |
| Terminated | A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenou NCT04272203 | AbbVie | Phase 1 |
| Completed | A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acut NCT04102020 | AbbVie | Phase 3 |
| Completed | A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy o NCT04202003 | TJ Biopharma Co., Ltd. | Phase 1 / Phase 2 |
| Completed | A Study of the Effectiveness of Venetoclax Tablets in Adult Acute Myeloid Leukemia Participants Ineligible for NCT04253314 | AbbVie | — |
| Terminated | A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care A NCT04161885 | AbbVie | Phase 3 |
| Unknown | Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT NCT04284228 | NexImmune Inc. | Phase 1 / Phase 2 |
| Terminated | Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies NCT04230265 | AvenCell Europe GmbH | Phase 1 |
| Terminated | A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combi NCT04029688 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Terminated | Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Th NCT03969420 | Sumitomo Pharma America, Inc. | Phase 2 |
| Completed | Remote Outpatient Temperature Monitoring for Early Detection of Febrile Neutropenia After Chemotherapy NCT04081753 | Augusta University | N/A |
| Recruiting | A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies NCT06550713 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Unknown | Molecular Diagnostic Platform for AML NCT04446741 | PETHEMA Foundation | — |
| Completed | A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Ac NCT04079296 | Astellas Pharma Global Development, Inc. | Phase 1 / Phase 2 |
| Completed | A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Sett NCT03941964 | AbbVie | Phase 3 |
| Terminated | HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Mye NCT03940352 | Novartis Pharmaceuticals | Phase 1 |
| Completed | A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory NCT03730012 | Astellas Pharma Global Development, Inc. | Phase 1 / Phase 2 |
| Terminated | Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML NCT03922100 | Nerviano Medical Sciences | Phase 1 / Phase 2 |
| Active Not Recruiting | TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in NCT03849651 | St. Jude Children's Research Hospital | Phase 2 |
| Completed | The Role and Mechanism of TCR-T Cells in Immunotherapy for Acute Myeloid Leukemia NCT06904859 | Shenzhen University General Hospital | EARLY_Phase 1 |
| Terminated | Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML NCT04402723 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1 |
| Completed | Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute NCT03723681 | Daiichi Sankyo Co., Ltd. | Phase 1 |
| Active Not Recruiting | Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MD NCT03613532 | Jacqueline Garcia, MD | Phase 1 |
| Completed | A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Rela NCT03625505 | AbbVie | Phase 1 |
| Withdrawn | Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leuk NCT03699384 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Terminated | Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors NCT03615105 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 NCT03512197 | Novartis Pharmaceuticals | Phase 3 |
| Terminated | Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remissi NCT03709576 | Milton S. Hershey Medical Center | Phase 2 |
| Terminated | A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML NCT03547115 | MEI Pharma, Inc. | Phase 1 |
| Completed | A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT03441555 | AbbVie | Phase 1 |
| Terminated | A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With Relapsed/Refractory Acute NCT03360006 | AbbVie | Phase 1 |
| Terminated | A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML) NCT03125876 | Sunshine Lake Pharma Co., Ltd. | Phase 1 |
| Completed | A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed o NCT03236857 | AbbVie | Phase 1 |
| Unknown | IDH1/IDH2 Mutation Frequency in Acute Myeloblastic Patients NCT03204838 | Hospital General de Mexico | — |
| Completed | A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Na NCT03069352 | AbbVie | Phase 3 |
| Completed | Allogeneic HCT Using Conditioning Regimen of BuFluATG for AML CR1 NCT07155382 | Asan Medical Center | — |
| Active Not Recruiting | A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With NCT02993523 | AbbVie | Phase 3 |
| Terminated | Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome NCT02749708 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Completed | A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Thera NCT02927262 | Astellas Pharma Global Development, Inc. | Phase 2 |
| Recruiting | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases NCT01962636 | Masonic Cancer Center, University of Minnesota | N/A |
| Terminated | Leukemia Stem Cell Detection in Acute Myeloid Leukemia NCT02927938 | Wake Forest University Health Sciences | Phase 3 |
| Withdrawn | A Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia NCT02826642 | Novartis Pharmaceuticals | Phase 1 |
| Completed | A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Tre NCT02752035 | Astellas Pharma Global Development, Inc. | Phase 3 |
| Active Not Recruiting | Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haplo NCT02790515 | St. Jude Children's Research Hospital | Phase 2 |
| Terminated | Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY NCT02992860 | GWT-TUD GmbH | Phase 2 |
| Recruiting | Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML NCT02781883 | Bio-Path Holdings, Inc. | Phase 2 |
| Completed | Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia NCT02658487 | Vanderbilt-Ingram Cancer Center | Phase 2 |
| Terminated | The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plu NCT02648932 | University of Chicago | Phase 2 |
| Terminated | Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodys NCT02198482 | University of Ulm | Phase 2 |
| Terminated | Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid NCT03071276 | St. Jude Children's Research Hospital | Phase 2 |
| Withdrawn | Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrom NCT01520805 | Cornerstone Pharmaceuticals | Phase 2 |
| Completed | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Ind NCT02649790 | Karyopharm Therapeutics Inc | Phase 1 / Phase 2 |
| Completed | Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS NCT02626715 | Randy Windreich | Phase 2 |
| Completed | Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH NCT02492737 | Agios Pharmaceuticals, Inc. | Phase 1 |
| Terminated | Treatment of Elderly AML Patients With Induction Chemotherapy Followed by G-CSF-Mobilized Stem Cells From Hapl NCT02519712 | Memorial Sloan Kettering Cancer Center | N/A |
| Terminated | Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML NCT02532010 | Weill Medical College of Cornell University | Phase 2 |
| Terminated | Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients NCT02433483 | St. Jude Children's Research Hospital | Phase 2 |
| Completed | A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer NCT02391480 | AbbVie | Phase 1 |
| Withdrawn | Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome f NCT02269579 | Jazz Pharmaceuticals | Phase 2 |
| Withdrawn | Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS NCT02204020 | University of Pittsburgh | Phase 2 |
| Terminated | Study of Ibrutinib in Subjects With Acute Myeloid Leukemia NCT02351037 | Pharmacyclics LLC. | Phase 2 |
| Recruiting | Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Inductio NCT02416388 | University Hospital, Angers | Phase 2 / Phase 3 |
| Terminated | Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML NCT02255162 | Massachusetts General Hospital | Phase 1 |
| Unknown | "InDACtion" vs "3+7" Induction in AML NCT02172872 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 |
| Terminated | Yoga Fatigue Study NCT02134782 | The Hospital for Sick Children | N/A |
| Terminated | Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation NCT02259348 | St. Jude Children's Research Hospital | Phase 2 |
| Completed | 10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1 NCT02252107 | Radboud University Medical Center | Phase 2 |
| Completed | Study Evaluating Venetoclax in Subjects With Hematological Malignancies NCT02265731 | AbbVie | Phase 1 / Phase 2 |
| Completed | Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia NCT02113982 | Stemline Therapeutics, Inc. | Phase 1 / Phase 2 |
| Completed | Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic NCT02212561 | St. Jude Children's Research Hospital | Phase 1 |
| Completed | An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Fo NCT02238925 | Jazz Pharmaceuticals | Phase 2 |
| Completed | Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) NCT02013648 | University of Ulm | Phase 3 |
| Completed | Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Pati NCT02181660 | Astellas Pharma Inc | Phase 1 |
| Completed | Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Ty NCT03047083 | Astellas Pharma Global Development, Inc. | — |
| Completed | Selinexor (KPT-330) in Older Patients With Relapsed AML NCT02088541 | Karyopharm Therapeutics Inc | Phase 2 |
| Completed | Study of the Glutaminase Inhibitor CB-839 in Leukemia NCT02071927 | Calithera Biosciences, Inc | Phase 1 |
| Completed | Pilot Study Efficacy and Tolerance Fish Oil Emulsion Daunorubicin and Cytarabine Treatment of AML Younger Pati NCT01999413 | French Innovative Leukemia Organisation | Phase 2 |
| Completed | Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT NCT01772953 | Center for International Blood and Marrow Transplant Research | Phase 2 |
| Completed | Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients NCT01929408 | Fred Hutchinson Cancer Center | — |
| Completed | Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM NCT01816230 | Gamida Cell ltd | Phase 1 / Phase 2 |
| Completed | Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders NCT01758042 | Massachusetts General Hospital | N/A |
| Completed | AML-MDS Novel Prognostic Tests Clinical Study NCT01685619 | Nova Scotia Health Authority | — |
| Completed | A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS NCT01613976 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia NCT01629082 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 |
| Terminated | Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler NCT01463410 | Skyline Diagnostics BV | — |
| Terminated | Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS NCT01442714 | Stanford University | Phase 2 |
| Completed | Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia NCT01373515 | Mendus | Phase 1 / Phase 2 |
| Completed | Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligi NCT01237808 | University of Ulm | Phase 3 |
| Completed | Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and NCT01180322 | University of Ulm | Phase 2 |
| Completed | Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute NCT01242774 | Novartis Pharmaceuticals | Phase 1 |
| Recruiting | Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL) NCT03188874 | Technische Universität Dresden | — |
| Recruiting | Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Le NCT01252485 | University of Ulm | — |
| Completed | Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML) NCT01147939 | Clavis Pharma | Phase 3 |
| Completed | Allogenic Stem Cell Transplantation for Children, Adolescents and Young Adults With Relapsed or Refractory AML NCT00606723 | Hannover Medical School | Phase 3 |
| Terminated | Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia NCT01034592 | Jason Robert Gotlib | Phase 1 |
| Completed | Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) NCT00850382 | University of Ulm | Phase 1 / Phase 2 |
| Completed | Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia NCT00890929 | Stanford University | Phase 1 / Phase 2 |
| Completed | Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Le NCT00893373 | Technische Universität Dresden | Phase 2 |
| Terminated | Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acut NCT00666497 | Mirati Therapeutics Inc. | Phase 2 |
| Completed | Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies NCT00710528 | Gilead Sciences | Phase 1 |
| Completed | Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acu NCT00656617 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome Wi NCT00655395 | Viron Therapeutics Inc | Phase 1 / Phase 2 |
| Completed | Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior Allogene NCT01191957 | Gruppo Italiano Trapianto di Midollo Osseo | Phase 3 |
| Terminated | Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML NCT00568633 | Stanford University | Phase 3 |
| Terminated | Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia NCT00664677 | Erimos Pharmaceuticals | Phase 1 |
| Completed | Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers NCT00488592 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Completed | Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy NCT00433745 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Completed | Safety, Tolerability and Pharmacokinetics of CSL360 in the Treatment of Acute Myeloid Leukemia NCT00401739 | CSL Limited | Phase 1 |
| Terminated | Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation NCT00363467 | H. Lee Moffitt Cancer Center and Research Institute | N/A |
| Completed | Dendritic Cell Vaccination for Patients With Acute Myeloid Leukemia in Remission NCT00834002 | University Hospital, Antwerp | Phase 1 |
| Completed | PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia NCT00093600 | Novartis Pharmaceuticals | Phase 1 |
| Completed | AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome NCT00071006 | Pfizer | Phase 2 |
| Completed | Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies NCT00145613 | St. Jude Children's Research Hospital | Phase 2 |
| Completed | The Risk of Acute Myeloid Leukaemia in Patients With Ewing's Sarcoma NCT06659224 | asmaa salama ibrahim | — |
| Available | Expanded Access to Venetoclax NCT03123029 | AbbVie | — |
| Approved For Marketing | Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Rel NCT03070093 | Astellas Pharma Global Development, Inc. | — |
| No Longer Available | Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutate NCT03409081 | Astellas Pharma Global Development, Inc. | — |